Catalent Stock

Catalent ROE

Delisted·Dec 17, 2024

The Return on Equity (ROE) of Catalent (CTLT) as of Aug 12, 2026 is -28.94 %. In the previous year, Return on Equity (ROE) was -5.01 % — a change of 478.18% (lower).

ROE

-28.94 %

YoY

478.18%

Last updated:

In 2026, Catalent's return on equity (ROE) was -28.94 %, a 478.18% increase from the -5.01 % ROE in the previous year.

Access this data via the Eulerpool API

Catalent Stock analysis

What does Catalent do? Catalent Inc is a global leader in advanced active ingredients and medical products, as well as solutions for drug development and manufacturing. The company was founded in 1933 by the Schering brothers in the USA and has become one of the preferred partners in the pharmaceutical industry due to its innovation, flexibility, and reliability. Catalent's business model is based on providing high-quality services and products that contribute to improving human health. The company offers a wide range of solutions, from active ingredient development to drug formulation and manufacturing, clinical trials, and product packaging. Through this comprehensive offering, Catalent helps its customers accelerate their drug development and product launch. The company is divided into different business sectors with specialized solutions, including the manufacturing of biopharmaceuticals such as antibodies, cell therapies, and vaccines, as well as medical devices, active ingredient manufacturing, and pharmaceutical development and manufacturing. Catalent's services also include active ingredient development, assisting customers in all stages of drug development from identifying new active ingredients to optimizing production processes. The company specializes in formulating drugs into suitable delivery forms that ensure safe and effective use, offering a variety of oral, inhalable, and parenteral formulations. Catalent also provides clinical trials, testing the efficacy and safety of drugs in clinical trials. The company has state-of-the-art facilities and expertise to professionally and successfully support its customers in conducting clinical studies. Additionally, Catalent offers a wide range of packaging solutions, including glass bottles, plastic containers, aluminum tubes, and the finishing and packaging of finished drugs. The company has advanced production systems that enable quick and flexible packaging production in any desired size and shape. Overall, Catalent provides its customers with a comprehensive range of services and products that enable fast and effective drug development and market launch. The company's strong innovation and diverse range of expertise make it a preferred partner in the pharmaceutical industry. Catalent is one of the most popular companies on Eulerpool.

ROE Details

Decoding Catalent's Return on Equity (ROE)

Catalent's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Catalent's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Catalent's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Catalent’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Catalent stock

Return on Equity (ROE) of Catalent is -28.94 % in 2026.

Return on Equity (ROE) of Catalent changed from -5.01 % to -28.94 %, representing a 478.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Catalent since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Catalent with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Catalent

All Key Metrics — Catalent